Pharmapack 2021 opens entries for Patient-Centric Design Awards
The global pandemic continues to impact lots of industries and slow down business, but the pharma and packaging industries are striving to tackle new challenges to bring more faster and safer solutions to deliver medication to patients. The Pharmapack Awards continue to recognize companies which have invested in innovating to improve patient outcomes, while working within the confines of a highly regulated pharma industry and changing business model.
Launched in 1997, the Pharmapack Awards recognize all types of innovations in the field of pharmaceutical packaging and drug delivery devices which have significantly improved drug efficacy and user’s safety and addressed sustainability issues such as a reduced impact on the environment.
In the Health Product Category*, Pharmapack has partnered with HCPC (Healthcare Compliance Packaging Council) Europe to set up the “Patient-centric Design Award” to select outstanding patient-friendly, or patient-centric packaging or drug delivery solutions.
At Pharmapack Europe 2020, the Patient-centric Design Award was won by Creon® SD, developed by Abbott Healthcare Pvt Limited, a smart granule dosing device for dispensing of Pancreatin Mini-microspheres.
See the Pharmapack 2020 Winners list
Additionally, more than ten new patient-centric concepts were showcased in the Pharmapack Innovation Gallery. Two smart drug delivery devices, from Credence MedSystems and Nemera, and a Patient Support App from Rondo were rewarded in the Exhibitors’ innovation category by the Pharmapack 2020 Awards jury.
Watch the video of Pharmapack Awards 2020 Winners’ presentations
Pharmapack opens entries of Patient-centric Design Award for all pharma and medical companies who have launched a new health product with a patient-centric design with market authorisation after December 2019. The deadline for submitting your candidature is 9 April 2021.
The Awards ceremony will be held on the first day of Pharmapack 2021, with the conference and exhibition taking place from 19-20 May in Paris Expo, Porte des Versailles.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...